尽管公司缺少收入估计数,但Rhenman & Partners增加了Vertex制药公司持有量。 Rhenman & Partners increased Vertex Pharmaceuticals holdings despite the company missing earnings estimates.

Rhenman & Partners 资产管理AB公司将Vertex制药公司库存增加了4.7%,达到50 000股,价值2 014万美元,成为其投资组合中第15大股。 Rhenman & Partners Asset Management AB increased its holdings of Vertex Pharmaceuticals stock by 4.7% to 50,000 shares, worth $20.14 million, making it the 15th largest position in their portfolio. 尽管报告中没有预计的收益,每股收益为3.54美元,而预期的收益为3.99美元,但分析师仍然将Vertex药品评为"中等购买"的目标价为509.17美元. Despite reporting a missed earnings estimate, with $3.54 EPS compared to the expected $3.99, analysts still rate Vertex Pharmaceuticals as a "Moderate Buy" with a target price of $509.17. 这家公司专业从事囊性纤维化治疗, 市值为1218亿美元. The company specializes in cystic fibrosis treatments and has a market cap of $121.88 billion.